Will Dengue Vaccines Be Used in the Public Sector and if so, How? Findings from an 8-country Survey of Policymakers and Opinion Leaders

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Rafael Lozano et al.   LANCET

Development of a group A meningococcal conjugate vaccine,MenAfriVacTM

(2012) Carl Frasch et al.   Human Vaccines & Immunotherapeutics

Immune Response to Dengue Virus and Prospects for a Vaccine

(2011) Brian R. Murphy et al.   Annual Review of Immunology

Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

(2011) Jorge E. Osorio et al.   VACCINE

The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease

(2011) Beth-Ann G. Coller et al.   VACCINE

From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

(2011) Bruno Guy et al.   VACCINE

Dengue: a continuing global threat

(2010) Maria G. Guzman et al.   NATURE REVIEWS MICROBIOLOGY

Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience

(2010) R.A. Hajjeh et al.   VACCINE

Accelerating Policy Decisions to Adopt Haemophilus influenzae Type b Vaccine: A Global, Multivariable Analysis

(2010) Jessica C. Shearer et al.   PLOS MEDICINE

Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4Δ30-4995 in Healthy Adult Volunteers

(2009) Peter F. Wright et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Drugs, sex, money and power: An HPV vaccine case study

(2009) Marion Haas et al.   HEALTH POLICY